01:34 , Apr 1, 2015 |  BC Extra  |  Company News

Management tracks

Pfizer Inc. (NYSE:PFE) named Charles Mackay CSO of the company's inflammation and immunology research unit. Mackay is a research fellow at Monash University and chair of diabetes at the Charles Perkins Center within the Faculty...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Allegro Diagnostics, Veracyte deal

Veracyte will acquire diagnostic company Allegro for $7.8 million in cash and $13.2 million in Veracyte shares, or about 993,000 shares. Veracyte plans to launch Allegro's BronchoGen genomic test -- a test that uses...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

BronchoGen genomic test: Pivotal trial data

The U.S. pivotal AEGIS II trial in 1,331 current or former cigarette smokers undergoing bronchoscopy for suspicion of lung cancer showed that Allegro's BronchoGen genomic test used in conjunction with bronchoscopy met the primary endpoint...
00:46 , Apr 3, 2014 |  BC Extra  |  Clinical News

Allegro says BronchoGen improves lung cancer diagnosis

Allegro Diagnostics Inc. (Maynard, Mass.) said its BronchoGen genomic test used in conjunction with bronchoscopy met the primary endpoint of improved accuracy of lung cancer diagnosis vs. bronchoscopy alone in the pivotal AEGIS II trial....
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

BronchoGen genetic test diagnostic data

Data from the U.S. AEGIS I study in 330 current or former cigarette smokers undergoing bronchoscopy for suspicion of lung cancer showed that Allegro's BronchoGen genomic test had 77% sensitivity and 73% specificity for...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

BronchoGen genetic test update

Allegro completed enrollment in the U.S. AEGIS II trial in 1,320 current or former cigarette smokers comparing the company's BronchoGen genomic test in conjunction with bronchoscopy vs. bronchoscopy alone. Allegro Diagnostics Inc., Maynard, Mass....
07:00 , Oct 6, 2011 |  BC Innovations  |  Tools & Techniques

Lung cancer signatures in blood

U.S. researchers have profiled and compared the proteomes of multiple mouse models to identify plasma protein signatures that could aid the discovery of lung cancer biomarkers.1 Key questions include whether the blood biomarkers could be...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Financial News

Allegro Diagnostics financial update

Allegro Diagnostics raised $5.4 million in an extension of a series A round, bringing the total raised in the round to $9.4 million. Existing investors Kodiak Venture Partners and Catalyst Ventures participated in the extension....
07:00 , Jul 4, 2011 |  BC Week In Review  |  Company News

Allegro Diagnostics, Boston University, University of Utah Research Foundation deal

Allegro exclusively licensed IP from the university and the foundation covering its molecular testing platform, which utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Allegro...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Allegro Diagnostics management update

Allegro Diagnostics Inc., Boston, Mass.   Business: Diagnostic   Hired: Michael Webb as president, CEO and a director, formerly president and CEO of Anchor Therapeutics Inc.   ...